A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade?), in combination with paclitaxel and carboplatin in patients with advanced malignancies

Cynthia Ma; Sumithra J. Mandrekar; Steven R. Alberts; Gary A. Croghan; Aminah Jatoi; Joel M. Reid; Lorelei J. Hanson; Laura Bruzek; Angelina D. Tan; Henry C. Pitot; Charles Erlichman; John J. Wright; Alex A. Adjei

首页> 外文期刊>Cancer Chemotherapy and Pharmacology >A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade?), in combination with paclitaxel and carboplatin in patients with advanced malignancies

【24h】

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade?), in combination with paclitaxel and carboplatin in patients with advanced malignancies

机译：蛋白酶体抑制剂硼替佐米（PS-341，Velcade？）与紫杉醇和卡铂联合用于晚期恶性肿瘤患者的I期和药理学研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Bortezomib, a selective inhibitor of the 20S proteasome with activity in a variety of cancers, exhibits sequence-dependent synergistic cytotoxicity with taxanes and platinum agents. Two different treatment schedules of bortezomib in combination with paclitaxel and carboplatin were tested in this phase I study to evaluate the effects of scheduling on toxicities, pharmacodynamics and clinical activity.

机译：硼替佐米是20S蛋白酶体的选择性抑制剂，在多种癌症中均具有活性，它与紫杉烷类和铂类药物表现出序列依赖性的协同细胞毒性作用。在第一阶段的研究中，对硼替佐米联合紫杉醇和卡铂的两种不同的治疗方案进行了测试，以评估该方案对毒性，药效学和临床活性的影响。

著录项

来源
《Cancer Chemotherapy and Pharmacology》 |2007年第2期|207-215|共9页
作者
Cynthia Ma; Sumithra J. Mandrekar; Steven R. Alberts; Gary A. Croghan; Aminah Jatoi; Joel M. Reid; Lorelei J. Hanson; Laura Bruzek; Angelina D. Tan; Henry C. Pitot; Charles Erlichman; John J. Wright; Alex A. Adjei;
展开▼
作者单位

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

National Cancer Institute Bethesda MD USA;

Division of Medical Oncology Mayo Clinic 200 First Street SW Rochester MN 55905 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
PS-341; Ubiquitin–proteasome system; Chemotherapy;

机译：PS-341;泛素-蛋白酶体系统;化学疗法;

相似文献

外文文献
中文文献
专利

1. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). [J] . Li T, Ho L, Piperdi B, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2010,第1期

机译：蛋白酶体抑制剂硼替佐米（PS-341，Velcade）在未经化疗的晚期非小细胞肺癌（NSCLC）患者中进行的II期研究。
2. A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE￠) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2 [J] . F.Cardoso, Azambuja, C.Bernard, European Journal of Cancer Supplements . 2006,第2期

机译：蛋白酶体抑制剂PS-341（VELCADE ￠）与两种方案的曲妥珠单抗联合进行的I期，开放标签，剂量递增的研究，用于过度表达HER-的晚期乳腺癌（ABC）患者2
3. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group [J] . GilbertJ., LeeJ.W., ArgirisA., Head and neck: Journal for the sciences and specialities of the head and neck . 2013,第7期

机译：蛋白酶体抑制剂PS-341（硼替佐米）联合伊立替康或单独PS-341的II期2臂试验，在局部复发或转移性头颅鳞癌患者中，在病情发展时加用伊立替康颈部（E1304）：东方合作肿瘤小组的一项试验
4. Nonclinical Discovery and Development of Bortezomib (PS-341, VELCADE~(R)) a Proteasome Inhibitor for the Treatment of Cancer [C] . Bouchard PR, Juedes M, Nix D, Annual Meeting of the American Society for Veterinary Clinical Pathology . 2004

机译：Bortezomib（PS-341，Velcade〜（R）的非临床发现和发展）一种治疗癌症的蛋白酶体抑制剂
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Phase II 2-arm trial of the proteasome inhibitor PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group [O] . Jill Gilbert, Ju Whei Lee, Athanassios Argiris, -1

机译：II 2-ARM试验蛋白酶体抑制剂PS-341（Bortezomib）与Irinotecan或PS-341组合然后在患有头部局部复发或转移鳞状细胞癌的患者的进展时加入伊立替康。颈部（E1304）：东方合作肿瘤组的试验
7. The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I Study [O] . Davies Angela M., Ruel Christopher, Lara Primo N., 2008

机译：蛋白酶体抑制剂硼替佐米联合吉西他滨和卡铂治疗晚期非小细胞肺癌：加利福尼亚州癌症协会I期研究

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade?), in combination with paclitaxel and carboplatin in patients with advanced malignancies

摘要

著录项

相似文献

相关主题

期刊订阅